• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 

EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 

by Elena Iemma | Sep 2, 2026 | Blog, Featured

EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction Building on decades of leadership in computational immunology, EpiVax is introducing several AI-enabled enhancements to ISPRIâ„¢, its industry-leading in silico platform for assessing the immunogenicity...
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    

by Elena Iemma | Jun 23, 2026 | News

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services     EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded...
Advancing Immunogenicity Science: EpiVax in 2025 

Advancing Immunogenicity Science: EpiVax in 2025 

by Elena Iemma | Jan 12, 2026 | Blog, News

In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation

The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation

by Elena Iemma | Oct 22, 2025 | Blog

The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation If you know us, you know we love Tregs. Regulatory T cells (Tregs) are central to how we think about the immune system and nearly everything we do at EpiVax. So, we were thrilled to see this...
The Tregs as Medicine Symposium | Advances in Tolerance Research

The Tregs as Medicine Symposium | Advances in Tolerance Research

by Elena Iemma | Aug 19, 2025 | Blog

The Tregs as Medicine Symposium September 26, 2025 | The Westin Hotel, Meguro Tokyo The Tregs as Medicine: Tolerance and InTolerance Symposium will bring together leading scientists and clinicians to examine how regulatory T cells (Tregs) and tolerance...
« Older Entries

Recent Posts

  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}